Maryland Medicaid Pharmacy Preferred Drug List

Registration for Public Testimony

Classes to be Reviewed

Alzheimers Agents

Analgesics/Anesthetics, Topical

Androgenic Agents

Antibiotics, Vaginal

Antidepressants, Other

Antidepressants, SSRIs

Antiemetics

Antifungals, Oral

Antifungals, Topical

Antiparasitics, Topical

AntiParkinsons Agents

Antivirals, Oral

 Atopic Dermatitis

Bone Resorption Suppression and Related Agents

Bronchodilators, Anticholinergics

Bronchodilators, Beta Agonists

Cephalosporins and Related Agents

Cytokine and CAM Antagonists

Fluoroquinolones, Oral

Glucocorticoids, Inhaled

Hypoglycemics, Incretin Mimetics,/Enhancers

Hypoglycemics, Insulins

Intranasal Rhinitis Agents

Leukotriene Modifiers

Macrolides/Ketolides

NSAIDs

Ophthalmics for Allergic Conjunctivitis

Ophthalmics, Glaucoma Agents

Pancreatic Enzymes

Platelet Aggregation Inhibitors

Stimulants and Related Agents

New Categories

Antihyperuricemics, oral

Antipsychotics (formerly Atypical Antipsychotics)

Antivirals, Topical

Opthalmic Antibiotics (previously Opthalmics, Fluoroquinolones and Macrolides)

Opthalmic Antiinflammatories (previously Opthalmic NSAIDS)

Tetracyclines, Oral

Single Drug Reviews

Analgesics, Narcotics - Long Acting (Dilaudid liquid)

Anticonvulsants (Banzel, Vimpat)

Bladder Relaxants (Toviaz)

BPH Agents (Rapaflo)

Hypoglycemics, Meglitinides (Prandimet)

Lipotropics, Other (Trilipix)

Phosphate Binders (Eliphos)

Proton Pump Inhibitors (Kapidex, Prilosec suspension)

Ulcerative Colitis Agents (Apriso, Sfrowasa)

Public testimony at the August 20, 2009 Pharmacy and Therapeutics Committee meeting will be limited to fifteen (15) presentations:  twelve (12) speakers from the drug industry and three (3) representing consumer interests.  To the extent that the full allotment for either group does not pre-register to speak, representatives from the other group will be selected in their place.  In the event speakers are selected and fail to appear at the meeting, their time will be forfeited, and that slot will remain unfilled.  We will start calling on speakers at approximately 9:20 a.m.  This part of the meeting will last approximately one and one-half hours.  Speakers will be called upon to give their presentations in the order that their names are drawn in the speaker lottery.  The time available for each presentation is up to five minutes.  Thirty seconds before the end of the presentation, speakers will receive a warning that time has almost expired. 

The deadline for registering to speak at the August 20, 2009 meeting is August 6, 2009.  Only one speaker per company, or organization may register to speak.  In the case of subsidiaries of conglomerates, one speaker from each subsidiary may register to speak.  Speakers may share their time slots.  However, there may be only one time slot given to a company or subsidiary. 

In the event more speakers have registered than there are spaces available, a lottery will be held to select 15 companies and consumers at random on the day after the deadline.  A disinterested party in the presence of witnesses will draw the names.  All registrants will be notified within twenty-four hours of the drawing, whether or not they have been selected.  Winners will be advised of their position in the order of speakers. To register, potential speakers must provide their full name, phone number, the therapeutic class(es) and drug(s) they wish to cover, organization and place of business to Megan Shook of the Maryland Pharmacy Program.  Submit applications by e-mail, fax, U.S. mail or any recognized carrier.  E-mail submissions are preferred.  Potential speakers for the Thursday, August 20, 2009 P&T Committee meeting may submit their request using the form at MarylandPDLQuestions or fax them to 410.333.5398 or mail them to the Maryland Pharmacy Program, 201 W. Preston Street, Room 408, Baltimore, Maryland 21201.  If you have a change in your choice of person to speak, please notify Ms. Shook as soon as possible after the change. 

Speakers are asked to provide two business cards to the registration attendant at the meeting. Speakers' handout information should be submitted to the Maryland Pharmacy Program (MPP) electronically at least two days prior to the meeting. With permission from MPP staff, handouts may be submitted on the day of the meeting when signing in.  Bring at least 22 copies of any handout material to the registration attendant.  Pharmacy Program staff will distribute the handouts to the P&T Committee members and staff prior to speakers taking the microphone.  Handouts are limited to no more than two standard 8-1/2 by 11 inch pages of “bulleted” points (or one page front and back) per five-minute time-slot.   At the meeting, speakers are required to state their name, organization and city of business.  Audio-visual equipment will not be allowed because of the time constraint. 

Submission of Written Material to Committee 

Written information from consumers or drug manufacturing companies who are of the selected speakers may be submitted to the Pharmacy and Therapeutics Committee.  E-mail communication is preferred; however, it must be compatible with MS-Word or in Adobe® Acrobat® format.  The Pharmacy Program will forward e-mails received before August 13 to the members of the Committee.  Charts and graphs may be submitted in MS-Excel® or Adobe® Acrobat®.  Attach your material to an e-mail to: MarylandPDLQuestions@dhmh.state.md.us.   Hard copies of written information may be mailed or delivered to Megan Shook, Clinical Pharmacy Services Division, Room 408, Dept. of Health and Mental Hygiene, 201 W. Preston St., Baltimore, MD  21201.  If the information is contained on two pages or less, we will copy it and send it to the P&T Committee members.  If it is more than 2 pages, please enclose at least 13 copies packaged in individual envelopes with sufficient US postage attached. The Pharmacy Program will affix address labels to your envelopes and forward them to the P&T Committee members.  Materials received with insufficient postage will not be forwarded.  Binders and heavy material must be placed in individual padded envelopes.  To ensure sufficient time for review, the mailed material must be received at DHMH at least two weeks prior to the meeting.